Current approaches for identifying high-risk non-muscle invasive bladder cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30. PubMed PMID: 28055103; eng. DOI:10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017 Mar;71(3):447–461. PubMed PMID: 27324428; eng. DOI:10.1016/j.eururo.2016.05.041
   PubMed Web of Science ®Google Scholar
• Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer (Amsterdam, Netherlands). 2016 Jan 7;2(1):27–36. PubMed PMID: 27376122; PubMed Central PMCID: PMCPMC4927900. eng. Doi:10.3233/blc-150034
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016 Feb;69(2):231–244. PubMed PMID: 26091833; eng. DOI:10.1016/j.eururo.2015.05.050.
   PubMed Web of Science ®Google Scholar
• Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, et al. Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol. 2017 Jul 10 PubMed PMID: 28705539; eng. DOI:10.1016/j.eururo.2017.06.038
   Web of Science ®Google Scholar
• Chou R, Selph S, Buckley DI, et al. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. J Urol2017 May;197(5):1189–1199.
   Google Scholar
• Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009 Aug;56(2):247–256. PubMed PMID: 19409692; eng. DOI:10.1016/j.eururo.2009.04.038
   PubMed Web of Science ®Google Scholar
• Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet (London, England). 2009 Jul 18;374(9685):239–249. PubMed PMID: 19520422; eng. Doi:10.1016/s0140-6736(09)60491-8
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Van Der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466–5; discussion 475–7. PubMed PMID: 16442208; eng. DOI:10.1016/j.eururo.2005.12.031
   PubMed Web of Science ®Google Scholar
• MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol. 2007 Apr;51(4):889–97; discussion 897–8. PubMed PMID: 17095142; eng. DOI:10.1016/j.eururo.2006.10.037
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009 Nov;182(5):2195–2203. PubMed PMID: 19758621; eng. DOI:10.1016/j.juro.2009.07.016
   PubMed Web of Science ®Google Scholar
• Hernandez V, De La Pena E, Martin MD, et al. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol. 2011 Aug;29(4):409–414. PubMed PMID: 21190023; eng. DOI:10.1007/s00345-010-0635-2
   PubMed Web of Science ®Google Scholar
• Rosevear HM, Lightfoot AJ, Nepple KG, et al. Usefulness of the Spanish Urological Club for oncological treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guerin plus interferon-alpha. J Urol. 2011 Jan;185(1):67–71. PubMed PMID: 21074202; eng. DOI:10.1016/j.juro.2010.08.083
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin. Eur Urol. 2016 Jan;69(1):60–69. PubMed PMID: 26210894; eng. DOI:10.1016/j.eururo.2015.06.045
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol. 2011 Sep;60(3):423–430. PubMed PMID: 21621906; eng. DOI:10.1016/j.eururo.2011.05.033
   PubMed Web of Science ®Google Scholar
• Busato Junior WF, Almeida GL, Ribas CA, et al. EORTC risk model to predict progression in patients with non-muscle-invasive bladder cancer: is it safe to use in clinical practice? Clin Genitourin Cancer. 2016 Apr;14(2):176–182. PubMed PMID: 26444918; eng. DOI:10.1016/j.clgc.2015.09.005
   PubMed Web of Science ®Google Scholar
• Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am. 2015 Apr;29(2):237–52, viii. PubMed PMID: 25836932; eng. DOI:10.1016/j.hoc.2014.10.011
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Yutkin V, Shapiro A, et al. The response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer. Front Oncol. 2016;6:43. PubMed PMID: 27014622; PubMed Central PMCID: PMCPMC4791377. eng. DOI:10.3389/fonc.2016.00043
   PubMed Web of Science ®Google Scholar
• Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006 Mar;175(3 Pt 1):881–885. PubMed PMID: 16469571; eng. DOI:10.1016/s0022-5347(05)00423-4
   PubMed Web of Science ®Google Scholar
• Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep;24(5):517–523. PubMed PMID: 24921905; eng. DOI:10.1097/mou.0000000000000089
   PubMed Web of Science ®Google Scholar
• Willis DL, Fernandez MI, Dickstein RJ, et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr;193(4):1129–1134. PubMed PMID: 25254936; PubMed Central PMCID: PMCPMC4687395. eng. DOI:10.1016/j.juro.2014.09.092
   PubMedGoogle Scholar
• Raman JD, Jafri SM. Surgical management of bladder urothelial carcinoma with squamous differentiation. Urol Oncol. 2015 Oct;33(10):429–433. PubMed PMID: 26206104; eng. DOI:10.1016/j.urolonc.2015.06.010
   PubMed Web of Science ®Google Scholar
• Klaile Y, Schlack K, Boegemann M, et al. Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease? Transl Androl Urol. 2016 Oct;5(5):692–701. PubMed PMID: 27785426; PubMed Central PMCID: PMCPMC5071184. eng. DOI:10.21037/tau.2016.06.13
   PubMed Web of Science ®Google Scholar
• Royce TJ, Lin CC, Gray PJ, et al. Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: results from the National Cancer Data Base. Urol Oncol. 2017 Nov 18 PubMed PMID: 29162314; eng. DOI:10.1016/j.urolonc.2017.10.013.
   PubMed Web of Science ®Google Scholar
• Shah RB, Montgomery JS, Montie JE, et al. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2013 Nov;31(8):1650–1655. PubMed PMID: 22608543; eng. DOI:10.1016/j.urolonc.2012.04.009
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim M, Jeong CW, et al. Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis. Urol Oncol. 2014 Nov;32(8):1191–1199. PubMed PMID: 24954108; eng. DOI:10.1016/j.urolonc.2014.05.008
   PubMed Web of Science ®Google Scholar
• Cho KS, Seo HK, Joung JY, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol. 2009 Dec;182(6):2625–2630. PubMed PMID: 19836779; eng. DOI:10.1016/j.juro.2009.08.083
   PubMed Web of Science ®Google Scholar
• Mathieu R, Lucca I, Roupret M, et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Reviews Urol. 2016 Aug;13(8):471–479. PubMed PMID: 27431340; eng. DOI:10.1038/nrurol.2016.126
   PubMed Web of Science ®Google Scholar
• Dobruch J, Borowka A, Herr HW. Clinical value of transurethral second resection of bladder tumor: systematic review. Urology. 2014 Oct;84(4):881–885. PubMed PMID: 25129540; eng. DOI:10.1016/j.urology.2014.06.005
   PubMed Web of Science ®Google Scholar
• Divrik RT, Sahin AF, Yildirim U, et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010 Aug;58(2):185–190. PubMed PMID: 20303646; eng. DOI:10.1016/j.eururo.2010.03.007
   PubMed Web of Science ®Google Scholar
• Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. BJU Int. 2016 Jul;118(1):44–52. PubMed PMID: 26469362; PubMed Central PMCID: PMCPMC5502757. eng. DOI:10.1111/bju.13354
   PubMed Web of Science ®Google Scholar
• Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005 Aug;48(2):231–8; discussion 238. PubMed PMID: 15963635; eng. DOI:10.1016/j.eururo.2005.04.013
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur Urol. 2016 Jul;70(1):106–119. PubMed PMID: 26996659; eng. DOI:10.1016/j.eururo.2016.02.028
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Liu L, Vis AN, et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer Risk scores in primary T1 bladder cancer. BJU Int. 2012 Oct;110(8):1169–1176. PubMed PMID: 22448597; eng. DOI:10.1111/j.1464-410X.2012.10996.x
   PubMed Web of Science ®Google Scholar
• Colombo R, Hurle R, Moschini M, et al. Feasibility and clinical roles of different substaging systems at first and second transurethral resection in patients with T1 high-grade bladder cancer. European Urology Focus. 2016 Jun 15 PubMed PMID: 28753746; eng. DOI:10.1016/j.euf.2016.06.004.
   Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Mar 20;507(7492):315–322. PubMed PMID: 24476821; PubMed Central PMCID: PMCPMC3962515. eng. Doi:10.1038/nature12965
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10;25(2):152–165. PubMed PMID: 24525232; PubMed Central PMCID: PMCPMC4011497. eng. DOI:10.1016/j.ccr.2014.01.009
   PubMed Web of Science ®Google Scholar
• Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Reviews Dis Primers. 2017 Apr 13;3:17022. PubMed PMID: 28406148; eng. DOI:10.1038/nrdp.2017.22
   PubMed Web of Science ®Google Scholar
• Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016 Jul 11;30(1):27–42. PubMed PMID: 27321955; eng. DOI:10.1016/j.ccell.2016.05.004.
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002 May;41(5):523–531. PubMed PMID: 12074794; eng.
   PubMed Web of Science ®Google Scholar
• Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol. 2003 Aug;170(2 Pt 1):428–432. PubMed PMID: 12853792; eng. DOI:10.1097/01.ju.0000075054.38441.2d
   PubMed Web of Science ®Google Scholar
• Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010 Nov;184(5):1907–1913. PubMed PMID: 20850152; PubMed Central PMCID: PMCPMC4327891. eng. DOI:10.1016/j.juro.2010.06.148
   PubMed Web of Science ®Google Scholar
• Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol. 2010 Apr;57(4):595–606. PubMed PMID: 20004052; eng. DOI:10.1016/j.eururo.2009.11.041
   PubMed Web of Science ®Google Scholar
• Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005 Sep;174(3):862–6; discussion 866. PubMed PMID: 16093971; eng. DOI:10.1097/01.ju.0000169257.19841.2a
   PubMed Web of Science ®Google Scholar
• Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul;178(1):68–73; discussion 73. PubMed PMID: 17499291; eng. DOI:10.1016/j.juro.2007.03.028
   Web of Science ®Google Scholar
• Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology. 2002 Dec;60(6):1025–1028. PubMed PMID: 12475663; eng.
   PubMed Web of Science ®Google Scholar
• Mowatt G, N’Dow J, Vale L, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care. 2011 Jan;27(1):3–10. PubMed PMID: 21262078; eng. DOI:10.1017/s0266462310001364
   PubMed Web of Science ®Google Scholar
• Rink M, Babjuk M, Catto JW, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013 Oct;64(4):624–638. PubMed PMID: 23906669; eng. DOI:10.1016/j.eururo.2013.07.007
   PubMed Web of Science ®Google Scholar
• Gakis G, Fahmy O. Systematic review and meta-analysis on the impact of hexaminolevulinate- versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer. Bladder cancer (Amsterdam, Netherlands). 2016 Jul 27;2(3):293–300. PubMed PMID: 27500197; PubMed Central PMCID: PMCPMC4969683. eng. Doi:10.3233/blc-160060
   PubMed Web of Science ®Google Scholar
• Shen P, Yang J, Wei W, et al. Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. BJU Int. 2012 Sep;110(6 Pt B):E209–15. PubMed PMID: 22288379; eng. DOI:10.1111/j.1464-410X.2011.10892.x
   PubMedGoogle Scholar
• Yuan H, Qiu J, Liu L, et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PloS One. 2013;8(9):e74142. PubMed PMID: 24058522; PubMed Central PMCID: PMCPMC3772837. eng. DOI:10.1371/journal.pone.0074142
   PubMed Web of Science ®Google Scholar
• Chou R, Selph S, Buckley DI, et al. Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: systematic review and meta-analysis. J Urol. 2017 Mar;197(3 Pt 1):548–558. PubMed PMID: 27780784; eng. DOI:10.1016/j.juro.2016.10.061
   PubMed Web of Science ®Google Scholar
• Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013 Nov;64(5):846–854. PubMed PMID: 23602406; eng. DOI:10.1016/j.eururo.2013.03.059
   PubMed Web of Science ®Google Scholar
• Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int. 2011 Dec;108(11):1703–1707. PubMed PMID: 21777364; eng. DOI:10.1111/j.1464-410X.2011.10485.x
   PubMed Web of Science ®Google Scholar
• Lee JY, Cho KS, Kang DH, et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer. 2015 Aug 1;15:566. 10.1186/s12885-015-1571-8. PubMed PMID: 26232037; PubMed Central PMCID: PMCPMC4521364. eng.
   PubMed Web of Science ®Google Scholar
• Ray Er Tk, Ajayo L, et al. The true value of Hexvix photodynamic diagnosis following intravesical bacille Calmette Guerin treatment for superficial bladder cancer [abstract 1583]. J Urol. 2007;177(S4):524.
   Google Scholar
• Naselli A, Introini C, Timossi L, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol. 2012 May;61(5):908–913. PubMed PMID: 22280855; eng. DOI:10.1016/j.eururo.2012.01.018
   PubMed Web of Science ®Google Scholar
• Kang W, Cui Z, Chen Q, et al. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis. Oncotarget. 2017 Apr 04;8(14):23880–23890. PubMed PMID: 27823975; PubMed Central PMCID: PMCPMC5410352. eng. DOI:10.18632/oncotarget.13054
   PubMedGoogle Scholar
• Zheng C, Lv Y, Zhong Q, et al. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012 Dec;110(11 Pt B):E680–7. PubMed PMID: 22985502; eng. DOI:10.1111/j.1464-410X.2012.11500.x
   PubMed Web of Science ®Google Scholar
• Naito S, Algaba F, Babjuk M, et al. The clinical research office of the endourological society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol. 2016 Sep;70(3):506–515. PubMed PMID: 27117749; eng. DOI:10.1016/j.eururo.2016.03.053.
   PubMed Web of Science ®Google Scholar
• Chang SSBS, Chou R, Clark E, et al. American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline. inventor; American Urological Association Education and Research, Inc. 2016.
   Google Scholar
• Sonn GA, Jones SN, Tarin TV, et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol. 2009 Oct;182(4):1299–1305. PubMed PMID: 19683270; eng. DOI:10.1016/j.juro.2009.06.039
   PubMed Web of Science ®Google Scholar
• Wu K, Liu JJ, Adams W, et al. Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy. Urology. 2011 Jul;78(1):225–231. PubMed PMID: 21601243; PubMed Central PMCID: PMCPMC4038103. eng. DOI:10.1016/j.urology.2011.02.057
   PubMed Web of Science ®Google Scholar
• Bonnal JL, Rock A Jr., Gagnat A, et al. Confocal laser endomicroscopy of bladder tumors associated with photodynamic diagnosis: an ex vivo pilot study. Urology. 2012 Nov;80(5):1162 e1–5. PubMed PMID: 22950991; eng. DOI:10.1016/j.urology.2012.06.035
   Web of Science ®Google Scholar
• Goh AC, Tresser NJ, Shen SS, et al. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008 Jul;72(1):133–137. PubMed PMID: 18598789; eng. DOI:10.1016/j.urology.2008.02.002
   PubMed Web of Science ®Google Scholar
• Gladkova N, Kiseleva E, Streltsova O, et al. Combined use of fluorescence cystoscopy and cross-polarization OCT for diagnosis of bladder cancer and correlation with immunohistochemical markers. J Biophotonics. 2013 Sep;6(9):687–698. PubMed PMID: 23420564; eng. DOI:10.1002/jbio.201200105
   PubMed Web of Science ®Google Scholar
• Kassouf W, Traboulsi SL, Schmitz-Drager B, et al. Follow-up in non-muscle-invasive bladder cancer-international bladder cancer network recommendations. Urol Oncol. 2016 Oct;34(10):460–468. PubMed PMID: 27368880; eng. DOI:10.1016/j.urolonc.2016.05.028
   PubMed Web of Science ®Google Scholar
• Yafi FA, Brimo F, Steinberg J, et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015 Feb;33(2):66 e25–31. PubMed PMID: 25037483; eng. DOI:10.1016/j.urolonc.2014.06.008
   Web of Science ®Google Scholar
• Van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005 Jun;47(6):736–748. PubMed PMID: 15925067; eng. DOI:10.1016/j.eururo.2005.03.014
   PubMed Web of Science ®Google Scholar
• Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008 Nov-Dec;26(6):646–651. PubMed PMID: 18367109; eng. DOI:10.1016/j.urolonc.2007.06.002
   PubMed Web of Science ®Google Scholar
• Hatzichristodoulou G, Kubler H, Schwaibold H, et al. Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek(R) and ELISA. Anticancer Res. 2012 Nov;32(11):5093–5097. PubMed PMID: 23155286; eng.
   PubMed Web of Science ®Google Scholar
• Wang Z, Que H, Suo C, et al. Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis. Oncotarget. 2017 Nov 21;8(59):100648–100656. PubMed PMID: 29246009; PubMed Central PMCID: PMCPMC5725051. eng. DOI:10.18632/oncotarget.22065
   PubMedGoogle Scholar
• Guo A, Wang X, Gao L, et al. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: a meta-analysis. Canadian Urologl Assoc Jl = Journal De l’Association Des Urologues Du Canada. 2014 May;8(5–6):E347–52. PubMed PMID: 24940462; PubMed Central PMCID: PMCPMC4039599. eng. DOI:10.5489/cuaj.1668
   PubMedGoogle Scholar
• Glas AS, Roos D, Deutekom M, et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. 2003 Jun;169(6):1975–1982. PubMed PMID: 12771702; eng. DOI:10.1097/01.ju.0000067461.30468.6d
   PubMed Web of Science ®Google Scholar
• Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010 Jan;14(4):1–331, iii-iv. PubMed PMID: 20082749; eng. DOI:10.3310/hta14040
   Web of Science ®Google Scholar
• Lotan Y, O’Sullivan P, Raman JD, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017 Aug;35(8):531.e15–531.e22. PubMed PMID: 28366272; eng. DOI:10.1016/j.urolonc.2017.03.008.
   Web of Science ®Google Scholar
• O’Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012 Sep;188(3):741–747. PubMed PMID: 22818138; eng. DOI:10.1016/j.juro.2012.05.003
   PubMed Web of Science ®Google Scholar
• Turker P, Bostrom PJ, Wroclawski ML, et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int. 2012 Sep;110(6):804–811. PubMed PMID: 22321341; eng. DOI:10.1111/j.1464-410X.2012.10939.x
   PubMed Web of Science ®Google Scholar
• Huang YL, Chen J, Yan W, et al. Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis. Tumour Bio:J Int Soc Oncodevelopmental Biol Med. 2015 May;36(5):3137–3145. PubMed PMID: 25854170; eng. DOI:10.1007/s13277-015-3352-z
   PubMed Web of Science ®Google Scholar
• Gleichenhagen J, Arndt C, Casjens S, et al. Evaluation of a new survivin ELISA and UBC((R)) rapid for the detection of bladder cancer in urine. Int J Mol Sci. 2018 Jan 11;19(1). PubMed PMID: 29324722; eng.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Li R, O’Donnell MA, et al. Predicting response to intravesical bacillus Calmette-Guerin immunotherapy: are we there yet? A systematic review. Eur Urol. 2017 Oct 18 PubMed PMID: 29055653; eng. DOI:10.1016/j.eururo.2017.10.003
   Web of Science ®Google Scholar
• Lotan Y, Bensalah K, Ruddell T, et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2008 Jun;179(6):2164–2169. PubMed PMID: 18423745; eng. DOI:10.1016/j.juro.2008.01.105
   PubMed Web of Science ®Google Scholar
• Mbeutcha A, Lucca I, Mathieu R, et al. Current status of urinary biomarkers for detection and surveillance of bladder cancer. Urol Clin North Am. 2016 Feb;43(1):47–62. PubMed PMID: 26614028; eng. DOI:10.1016/j.ucl.2015.08.005
   PubMed Web of Science ®Google Scholar
• Kavalieris L, O’Sullivan P, Frampton C, et al. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. J Urol. 2017 Jun;197(6):1419–1426. PubMed PMID: 27986532; eng. DOI:10.1016/j.juro.2016.12.010
   PubMed Web of Science ®Google Scholar
• Todenhofer T, Hennenlotter J, Esser M, et al. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer. Dis Markers. 2014;2014:973406. PubMed PMID: 25587206; PubMed Central PMCID: PMCPMC4284969. eng. DOI:10.1155/2014/973406
   PubMedGoogle Scholar
• Go H, Kim PJ, Jeon YK, et al. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: association with poor clinical outcome and potential therapeutic target. European J Cancer (Oxford, England: 1990). 2015 Sep;51(14):1937–1945. PubMed PMID: 26238015; eng. DOI:10.1016/j.ejca.2015.07.021
   PubMed Web of Science ®Google Scholar
• Behnsawy HM, Miyake H, Abdalla MA, et al. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Urol Oncol. 2011 Sep-Oct;29(5):495–501. PubMed PMID: 19914103; eng. DOI:10.1016/j.urolonc.2009.08.002
   PubMed Web of Science ®Google Scholar
• Mangrud OM, Gudlaugsson E, Skaland I, et al. Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder. Hum Pathol. 2014 Jul;45(7):1496–1503. PubMed PMID: 24796506; eng. DOI:10.1016/j.humpath.2014.03.001
   PubMed Web of Science ®Google Scholar
• Kim K, Cho YM, Park BH, et al. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer. Int J Clin Exp Pathol. 2015;8(1):743–750. PubMed PMID: 25755769; PubMed Central PMCID: PMCPMC4348879. eng.
   PubMed Web of Science ®Google Scholar
• Boman K, Andersson G, Wennersten C, et al. Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study. Biomarker Res. 2017;5:10. PubMed PMID: 28293425; PubMed Central PMCID: PMCPMC5348745. eng. DOI:10.1186/s40364-017-0090-y
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Hemdan T, Segersten U. Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer. Urol Oncol. 2017 Aug;35(8):532 e1–532 e6. PubMed PMID: 28389159; eng. DOI:10.1016/j.urolonc.2017.03.010
   Web of Science ®Google Scholar
• Fristrup N, Birkenkamp-Demtroder K, Reinert T, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol. 2013 Feb;182(2):339–349. PubMed PMID: 23201130; eng. DOI:10.1016/j.ajpath.2012.10.017
   PubMed Web of Science ®Google Scholar
• Passoni N, Gayed B, Kapur P, et al. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Urol Oncol. 2016 Nov;34(11):485 e7–485 e14. PubMed PMID: 27637323; eng. DOI:10.1016/j.urolonc.2016.05.014
   Web of Science ®Google Scholar
• Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer. 2013 Sep 17;109(6):1460–1466. PubMed PMID: 23982601; PubMed Central PMCID: PMCPMC3776972. eng. DOI:10.1038/bjc.2013.372
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Stephenson AJ, Kattan MW. Are nomograms needed in the management of bladder cancer? Urol Oncol. 2010 Jan-Feb;28(1):102–107. PubMed PMID: 20123358; eng. DOI:10.1016/j.urolonc.2009.04.020
   PubMed Web of Science ®Google Scholar
• Shariat SF, Zippe C, Ludecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol. 2005 May;173(5):1518–1525. PubMed PMID: 15821471; eng. DOI:10.1097/01.ju.0000154696.48217.75
   PubMed Web of Science ®Google Scholar
• Pan CC, Chang YH, Chen KK, et al. Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder. J Clin Pathol. 2010 Oct;63(10):910–915. PubMed PMID: 20876324; eng. DOI:10.1136/jcp.2010.079764
   PubMed Web of Science ®Google Scholar
• Ali-El-Dein B, Sooriakumaran P, Trinh QD, et al. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre. BJU Int. 2013 Jun;111(8):E331–41. PubMed PMID: 23445082; eng. DOI:10.1111/bju.12026
   PubMed Web of Science ®Google Scholar
• Kluth LA, Black PC, Bochner BH, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015 Aug;68(2):238–253. PubMed PMID: 25709027; eng. DOI:10.1016/j.eururo.2015.01.032
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010 Sep;58(3):433–441. PubMed PMID: 20646825; eng. DOI:10.1016/j.eururo.2010.05.043
   PubMed Web of Science ®Google Scholar
• Lamy P, Nordentoft I, Birkenkamp-Demtroder K, et al. Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma. Cancer Res. 2016 Oct 1;76(19):5894–5906. PubMed PMID: 27488526; eng. DOI:10.1158/0008-5472.can-16-0436
   PubMed Web of Science ®Google Scholar